S. Rigatos

588 citations

31 papers · 497 indexed · h-index 13

Impact in

Oncology top 10%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
Cancer Research
- Cancer Genomics and Diagnostics

Papers in

Oncology 25
- Cancer Treatment and Pharmacology 13
- Colorectal Cancer Treatments and Studies 8
- Lung Cancer Research Studies 4
- Pancreatic and Hepatic Oncology Research 3
Cancer Research 7
- Breast Cancer Treatment Studies 3

Co-authors: George P. Stathopoulos G. Stathopoulos George Fountzilas J. Stathopoulos Gerasimos Aravantinos Vassilis Georgoulias N. Malamos Sofia Agelaki
Journals: Oncology Reports (4 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)Anti-Cancer Drugs (2 papers)
Partner nations: Greece United States China

In The Last Decade

S. Rigatos

31 papers receiving 479 citations

Peers

Countries citing papers authored by S. Rigatos

Since Specialization

Citations

This map shows the geographic impact of S. Rigatos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Rigatos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Rigatos more than expected).

Fields of papers citing papers by S. Rigatos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Rigatos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Rigatos. The network helps show where S. Rigatos may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. Rigatos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Rigatos Line = papers co-authored together S. Rigatos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study. PubMed ·George P. Stathopoulos, S. Rigatos, J. Stathopoulos	2010	11
2	Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival Digestive Diseases ·Epaminontas Samantas, Christos Dervenis, S. Rigatos	2007	14
3	Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer Cancer Chemotherapy and Pharmacology ·George P. Stathopoulos, N. Malamos, Gerasimos Aravantinos, S. Rigatos, Jürgen Lass, J. Stathopoulos, D. Skarlos	2006	10
4	Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study Cancer Chemotherapy and Pharmacology ·George P. Stathopoulos, Jürgen Lass, J. Stathopoulos, D. Skarlos, S. Rigatos, T. Giannakakis, Arifindi, D. Antoniou, A. Athanasiadis, Paul Harrision, J. Dimitroulis, Niki Georgatou, Daan W. Groenendijk	2005	12
5	Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study Cancer Chemotherapy and Pharmacology ·G. Stathopoulos, D. Tsavdaridis, N. Malamos, S. Rigatos, Christos Kosmas, Maryam Zamanian Daryoush, J. Stathopoulos, Ewan Whittaker Walker	2005	18
6	Phase I dose-finding study of capecitabine (X) with escalating irinotecan (I) and oxaliplatin (O) in patients (pts) with previously treated solid tumors Journal of Clinical Oncology ·Epaminontas Samantas, S. Rigatos, A. U. Gadjieva, Norihisa Yoda, P. Valabrega, I. K. (I.) Darsana, P H Evans, まゆみ青山, Gerasimos Aravantinos	2005	2
7	Treatment of non-small cell lung cancer with gefitinib (???Iressa???, ZD1839): the Greek experience with a compassionate-use program Anti-Cancer Drugs ·Evangelia Razis, D. Skarlos, Evangelos Briasoulis, Meletios Α. Dimopoulos, George Fountzilas, Sarah Louise, S. Rigatos, Petros Kopterides, Pr. Ait El Hadj L, Ândreas Adelino Andrade, Максим Євгенович Жидко, Arnold M. Barsky, Thomas Makatsoris, Johann Bloem, Savvas Papadopoulos, P. Kosmidis	2005	8
8	Efficacy and Tolerability of Oxaliplatin Plus Irinotecan 5-Fluouracil and Leucovorin Regimen in Advanced Stage Colorectal Cancer Patients Pretreated With Irinotecan 5-Fluouracil and Leucovorin American Journal of Clinical Oncology ·George P. Stathopoulos, S. Rigatos, Rafaela Aparecida de Almeida, Ewan Whittaker Walker, Evangelini Dimou	2005	11
9	Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial Annals of Oncology ·George P. Stathopoulos, M. Veslemes, Niki Georgatou, D. Antoniou, Paul Harrision, Daan W. Groenendijk, D. Tsavdaridis, S. Rigatos, J. Dimitroulis, Kaixin Xiong, Stelios Loukides, Kathryn F. Murphy, Catastral y de Estadística, Mncedisi Junior Manyoni, 康夫岩渕, Ping Yang, M. Zeng, 胡曰博, B. Nagamuruga, Khizar Hayat	2004	50
10	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) Anti-Cancer Drugs ·Jim Janinis, George P. Stathopoulos, Paul Nikolaidis, Haralabos P. Kalofonos, Anna Kalogera‐Fountzila, E. Samantas, Gerasimos Aravantinos, R Wlodarz, Mélissa Gignac, Thomas Makatsoris, S. Rigatos, Dimitrios Bafaloukos, Meletios Α. Dimopoulos, Karin Terfloth, George Fountzilas	2004	6
11	Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study Annals of Oncology ·G. Stathopoulos, K. Syrigos, Aristidis Polyzos, George Fountzilas, S. Rigatos, Nikolaos Ziras, 正幸中垣, ER Jian-yu, Nikolaos Androulakis, Gerasimos Aravantinos, A. Athanasiadis, Pavlos Papakotoulas, Vassilis Georgoulias	2004	48
12	Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer Annals of Oncology ·G. Stathopoulos, S. Rigatos, Meletios Α. Dimopoulos, T. Giannakakis, Achouri Imed Eddine, Charalambos Kouroussis, David Pickett, Gerasimos Aravantinos, N. Androulakis, Sofia Agelaki, J. Stathopoulos, Vassilis Georgoulias	2003	39
13	Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study Oncology Reports ·S. Rigatos, D. Tsavdaridis, Athanasios Athanasiadis, Rafaela Aparecida de Almeida, George Stathopoulos	2003	17
14	37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results European Journal of Cancer Supplements ·Gerasimos Aravantinos, G. Fountzlias, P. Kosmidis, Meletios Α. Dimopoulos, Benjamin Haley, N. Karelkhan, Dimitrios Bafaloukos, S. Rigatos, Васин А. С., D. Skarlos	2003	2
15	Paclitaxel and vinorelbine combination in advanced inoperable adenocarcinoma of the lung: a phase II study. PubMed ·George P. Stathopoulos, M. Veslemes, Niki Georgatou, Naansonou Patrick Lare, ANCA MARIA CIMPEAN, Daan W. Groenendijk, A.C Willams, S. Rigatos, Intriago Muñoz	2003	5
16	Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study. PubMed ·S. Rigatos, George P. Stathopoulos, Ismene Dontas, YU.V. TARANUKHA, Si Dong Liu, Panayotis E. Karayannacos, George Deliconstantinos	2002	8
17	Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer Annals of Oncology ·G. Stathopoulos, Dimitriοs Mavroudis, Νicolas Tsavaris, Ch. Kouroussis, Gerasimos Aravantinos, Sofia Agelaki, S. Kakolyris, S. Rigatos, Nehemias Lacerda, Vassilis Georgoulias	2001	58
18	Angiogenesis and Apoptosis-Related Protein (p53, bcl-2, and bax) Expression Versus Response of Gastric Adenocarcinomas to Paclitaxel and Carboplatin Chemotherapy American Journal of Clinical Oncology ·Alexandra Giatromanolaki, G. Stathopoulos, Michael I. Koukourakis, S. Rigatos, Z. Tonggung, Christos Kittas, George Fountzilas, Efthimios Sivridis	2001	9
19	Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin. Oncology Reports ·G. Stathopoulos, S. Rigatos, N. Malamos	1999	22
20	Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers European Journal of Cancer ·George P. Stathopoulos, S. Rigatos, Pavlos Papakostas, George Fountzilas	1997	22

About S. Rigatos

S. Rigatos is a scholar working on Oncology, Cancer Research, Otorhinolaryngology, Pulmonary and Respiratory Medicine and Hepatology, having authored 31 papers that have together received 497 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (4 papers), Gastric Cancer Management and Outcomes (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Breast Cancer Treatment Studies (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). The work is most often cited by research in Oncology (396 citations), Cancer Research (99 citations), Pulmonary and Respiratory Medicine (200 citations), Otorhinolaryngology (25 citations) and Hepatology (34 citations). S. Rigatos has collaborated with scholars based in Greece, United States and China. Frequent co-authors include George P. Stathopoulos, G. Stathopoulos, George Fountzilas, J. Stathopoulos, Gerasimos Aravantinos, Vassilis Georgoulias, N. Malamos, Sofia Agelaki, D. Tsavdaridis and A. Polyzos. Their work appears in journals such as Oncology Reports, Annals of Oncology, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact